Azemiglitazone
Azemiglitazone is a pharmaceutical compound that belongs to the class of thiazolidinediones, which are used primarily as antidiabetic drugs. These drugs function by improving insulin sensitivity in patients with type 2 diabetes mellitus.
Mechanism of Action[edit | edit source]
Azemiglitazone works by activating the peroxisome proliferator-activated receptor gamma (PPAR-γ), a type of nuclear receptor. Activation of PPAR-γ influences the transcription of various genes involved in glucose and lipid metabolism. This leads to an increase in insulin sensitivity in peripheral tissues, such as adipose tissue, skeletal muscle, and the liver.
Clinical Use[edit | edit source]
Azemiglitazone is primarily indicated for the management of type 2 diabetes mellitus. It is used to improve glycemic control in conjunction with diet and exercise. It may be used as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas.
Side Effects[edit | edit source]
Common side effects of azemiglitazone include:
- Weight gain
- Edema
- Increased risk of heart failure
Less common but serious side effects may include:
- Hepatotoxicity
- Increased risk of bone fractures
Contraindications[edit | edit source]
Azemiglitazone is contraindicated in patients with:
- Heart failure
- Severe hepatic impairment
- Known hypersensitivity to the drug or its components
Pharmacokinetics[edit | edit source]
Azemiglitazone is absorbed from the gastrointestinal tract and undergoes extensive metabolism in the liver. It is primarily excreted via the kidneys. The half-life of azemiglitazone allows for once-daily dosing.
Research and Development[edit | edit source]
Azemiglitazone is still under investigation in various clinical trials to better understand its efficacy and safety profile. Ongoing research aims to compare its effectiveness with other thiazolidinediones like pioglitazone and rosiglitazone.
See Also[edit | edit source]
- Thiazolidinedione
- Type 2 diabetes mellitus
- Insulin resistance
- Peroxisome proliferator-activated receptor
References[edit | edit source]
External Links[edit | edit source]
-
| Diabetes Drug Stub | |
|---|---|
| |
| This article about a diabetes drug is a stub. You can help WikiMD by expanding it. | |
| Related topics | Diabetes mellitus · Insulin · Hypoglycemia · Hyperglycemia |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
